Immunome, Inc. (IMNM) DCF Valuation

Immunome, Inc. (IMNM) DCF Valuation
  • Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • Predeterminadas Para Un Uso Rápido Y Eficiente
  • No Se Necesita Experiencia; Fáciles De Seguir

Immunome, Inc. (IMNM) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our Immunome, Inc. (IMNM) DCF Calculator enables you to evaluate Immunome's valuation using real-world financial data, offering complete flexibility to modify all essential parameters for improved projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019
AY2
2020
AY3
2021
AY4
2022
AY5
2023
FY1
2024
FY2
2025
FY3
2026
FY4
2027
FY5
2028
Revenue .0 .0 .0 .0 14.0 14.0 14.0 14.0 14.0 14.0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -9.7 -17.0 -23.9 -36.3 -28.3 8.4 8.4 8.4 8.4 8.4
EBITDA, % 100 100 100 100 -201.68 60 60 60 60 60
Depreciation .6 .8 .8 .6 .7 11.4 11.4 11.4 11.4 11.4
Depreciation, % 100 100 100 100 5.19 81.04 81.04 81.04 81.04 81.04
EBIT -10.3 -17.8 -24.7 -36.9 -29.0 8.4 8.4 8.4 8.4 8.4
EBIT, % 100 100 100 100 -206.87 60 60 60 60 60
Total Cash 2.5 39.8 49.2 20.3 138.1 14.0 14.0 14.0 14.0 14.0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .9 4.3 .8 .3
Account Receivables, % 100 100 100 100 2.06
Inventories .0 -.9 -4.3 -.8 .0 11.2 11.2 11.2 11.2 11.2
Inventories, % 100 100 100 100 0 80 80 80 80 80
Accounts Payable .5 1.2 3.1 2.4 3.3 11.9 11.9 11.9 11.9 11.9
Accounts Payable, % 100 100 100 100 23.62 84.72 84.72 84.72 84.72 84.72
Capital Expenditure -.2 -.6 -.1 -.2 -.8 -.2 -.2 -.2 -.2 -.2
Capital Expenditure, % 100 100 100 100 -5.93 -1.19 -1.19 -1.19 -1.19 -1.19
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -10.4 -17.1 -24.5 -37.5 -29.0 8.3 8.3 8.3 8.3 8.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -9.5 -16.2 -21.9 -37.8 -28.5 5.9 19.5 19.5 19.5 19.5
WACC, % 12.98 12.98 12.98 12.98 12.98 12.98 12.98 12.98 12.98 12.98
PV UFCF
SUM PV UFCF 56.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 20
Terminal Value 181
Present Terminal Value 98
Enterprise Value 155
Net Debt -97
Equity Value 252
Diluted Shares Outstanding, MM 20
Equity Value Per Share 12.71

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real IMNM financials.
  • Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
  • Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly observe the effects of your inputs on Immunome’s valuation.
  • Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.

Key Features

  • Comprehensive Data Access: Immunome’s historical financial statements and pre-filled projections.
  • Customizable Variables: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Insights: Monitor Immunome’s intrinsic value recalculating instantly.
  • Intuitive Visualizations: Dashboard charts present valuation outcomes and essential metrics clearly.
  • Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.

How It Works

  1. Download the Template: Gain immediate access to the Excel-based IMNM DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
  3. Instant Calculations: The model automatically recalculates Immunome’s intrinsic value.
  4. Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
  5. Analyze and Decide: Leverage the results to inform your investment or financial analysis.

Why Choose This Calculator for Immunome, Inc. (IMNM)?

  • Precision: Utilizes real Immunome financial data to ensure accuracy.
  • Adaptability: Built for users to easily adjust and test various inputs.
  • Efficiency: Eliminate the need to create a DCF model from the ground up.
  • Expert-Level: Crafted with the precision and usability expected by CFOs.
  • Accessible: Intuitive interface suitable for users without extensive financial modeling knowledge.

Who Should Use This Product?

  • Investors: Accurately assess Immunome, Inc.’s (IMNM) fair value prior to making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Immunome, Inc. (IMNM).
  • Consultants: Efficiently modify the template for valuation reports tailored to Immunome, Inc. (IMNM) clients.
  • Entrepreneurs: Acquire insights into the financial modeling practices employed by leading biotech firms like Immunome, Inc. (IMNM).
  • Educators: Employ it as a teaching resource to illustrate valuation methodologies relevant to Immunome, Inc. (IMNM).

What the Template Contains

  • Historical Data: Includes Immunome, Inc.'s (IMNM) past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Immunome, Inc.'s (IMNM) intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Immunome, Inc.'s (IMNM) financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.